RESMED INC RMD 88.03
Health Care · NYSE · Data as of 2026-10-30
RESMED INC (RMD) has delivered +12.0% annualized revenue growth, +20.0% earnings growth, and +6.7% dividend growth over 10 years of data. Ranked #26 of 1968 stocks overall and #3 of 260 in the Health Care sector by Steady Score.
About RESMED INC
Company Overview
ResMed develops cloud-connected medical devices and software for sleep apnea, chronic respiratory disease and care delivered outside hospitals. Its products include positive airway pressure devices, masks, ventilators, diagnostics, dental devices and accessories, supported by remote monitoring and therapy-management platforms. It also provides software for home medical equipment and residential-care organizations. The company sells through subsidiaries and distributors to providers and patients in more than 140 countries.
Read more
Business Model & Revenue
Revenue comes from sales of therapy devices and a continuing stream of replacement masks, cushions and accessories, plus subscriptions and services from cloud software. Home-care providers, distributors and healthcare systems are key customers, with reimbursement rules influencing patient access and demand. Connected devices transmit therapy data that supports adherence and provider workflows. ResMed reports Sleep and Breathing Health and Residential Care Software, though it agreed to sell the MatrixCare portion of the software segment.
Key Facts & Market Position
ResMed pairs durable treatment devices with regularly replaced patient interfaces and cloud-based monitoring, linking products used in the home to clinical and provider workflows. In June 2026 it acquired Noctrix Health, adding a device for restless legs syndrome. The planned MatrixCare divestiture excludes Brightree and MEDIFOX DAN and is intended to narrow the portfolio toward sleep, breathing and connected home care.